2022 World Conference on Lung Cancer (ePosters)-EP08.02-027. T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC

EP08.02-027. T790M Detection Rate After First-Line Treatment with Bevacizumab Plus 1st or 2nd Generation EGFR-TKI in Advanced NSCLC

Pdf Summary

Summary Not Available

Asset Subtitle

Chao-Chi Ho

Meta Tag

Speaker Chao-Chi Ho

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments